NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $57,725,271.93

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$110.75

▲ +1.76 (1.61%)

As of 03/14/2025 05:00 PM ET

Days: 30 | 90 | 365

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2025	Julie Cooke	Insider	Sell	1,551	$116.78	$181,125.78	19,544
2/13/2025	Kevin Charles Gorman	Director	Sell	5,844	$116.69	$681,936.36	521,618
2/13/2025	Matt Abernethy	CFO	Sell	2,558	$116.86	$298,927.88	34,775
2/10/2025	Julie Cooke	Insider	Sell	700	$118.28	$82,796.00	18,831
2/10/2025	Kevin Charles Gorman	Director	Sell	2,274	$118.37	$269,173.38	519,074
2/10/2025	Kyle Gano	CEO	Sell	980	$118.39	$116,022.20	137,658
2/3/2025	Ingrid Delaet	Insider	Sell	623	$149.29	$93,007.67	3,442
1/31/2025	Julie Cooke	Insider	Sell	1,740	$152.89	$266,028.60	18,202
1/31/2025	Kevin Charles Gorman	Director	Sell	2,707	$152.92	$413,954.44	517,030
1/31/2025	Kyle Gano	CEO	Sell	1,541	$152.87	$235,572.67	136,778
1/31/2025	Matt Abernethy	CFO	Sell	1,283	$152.87	$196,132.21	32,681
1/27/2025	Kevin Charles Gorman	Director	Sell	146,105	$149.46	$21,836,853.30	514,596
1/15/2025	Kyle Gano	CEO	Sell	65,000	$141.50	$9,197,500.00	135,392
12/31/2024	Ingrid Delaet	Insider	Sell	272	$138.10	$37,563.20	2,507
12/17/2024	Ingrid Delaet	Insider	Sell	1,091	$135.00	$147,285.00	2,507
11/29/2024	Jude Onyia	Insider	Sell	2,331	$126.29	$294,381.99	15,449
8/15/2024	William H. Rastetter	Director	Sell	14,250	$146.69	$2,090,332.50	37,491
8/13/2024	Gary A. Lyons	Director	Sell	11,570	$150.43	$1,740,475.10	119,047
8/13/2024	Ingrid Delaet	Insider	Sell	7,143	$150.10	$1,072,164.30	2,507
8/13/2024	Matt Abernethy	CFO	Sell	14,100	$150.38	$2,120,358.00	31,528
8/6/2024	Ingrid Delaet	Insider	Sell	273	$147.70	$40,322.10	6,607
8/1/2024	Julie Cooke	Insider	Sell	12,632	$153.26	$1,935,980.32	18,202
7/16/2024	Gary A. Lyons	Director	Sell	930	$150.03	$139,527.90	119,047
7/16/2024	Julie Cooke	Insider	Sell	900	$150.04	$135,036.00	18,202
7/1/2024	Julie Cooke	Insider	Sell	10,000	$140.19	$1,401,900.00	18,202
5/29/2024	Stephen A. Sherwin	Director	Sell	40,000	$133.46	$5,338,400.00	26,504
5/17/2024	Shalini Sharp	Director	Sell	1,106	$141.90	$156,941.40	994
5/15/2024	Matt Abernethy	CFO	Sell	15,000	$140.24	$2,103,600.00	31,528
5/14/2024	Gary A. Lyons	Director	Sell	12,500	$135.63	$1,695,375.00	116,947
5/6/2024	Ingrid Delaet	Insider	Sell	273	$140.55	$38,370.15	7,507
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055
11/30/2022	Eric Benevich	Insider	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Eric Benevich	Insider	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Eric Benevich	Insider	Sell	24,593	$125.33	$3,082,240.69	15,643
11/3/2022	Darin Lippoldt	Insider	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Darin Lippoldt	Insider	Sell	10,000	$120.09	$1,200,900.00	29,234
10/31/2022	Gary A. Lyons	Director	Sell	15,000	$114.76	$1,721,400.00	203,697
10/27/2022	Darin Lippoldt	Insider	Sell	4,923	$115.04	$566,341.92	29,234
10/17/2022	Eric Benevich	Insider	Sell	4,960	$110.82	$549,667.20	15,643
10/4/2022	Gary A. Lyons	Director	Sell	5,000	$110.54	$552,700.00	203,697
10/3/2022	David W. Boyer	Insider	Sell	1,437	$106.59	$153,169.83	4,214
8/12/2022	Malcolm Lloyd-Smith	Insider	Sell	21,533	$105.95	$2,281,421.35	18,888
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/14/2025	Lansforsakringar Fondforvaltning AB publ	32,446	$4.43M	0.1%	N/A	0.033%
3/4/2025	Siemens Fonds Invest GmbH	6,225	$0.85M	0.0%	N/A	0.006%
2/28/2025	Universal Beteiligungs und Servicegesellschaft mbH	68,029	$9.29M	0.0%	N/A	0.068%
2/20/2025	Mackenzie Financial Corp	55,221	$7.54M	0.0%	-36.2%	0.055%
2/20/2025	Forum Financial Management LP	1,859	$0.25M	0.0%	N/A	0.002%
2/20/2025	Peak Retirement Planning Inc.	7,630	$1.03M	0.7%	N/A	0.008%
2/19/2025	Toronto Dominion Bank	13,183	$1.80M	0.0%	+3.9%	0.013%
2/19/2025	GF Fund Management CO. LTD.	2,126	$0.29M	0.0%	N/A	0.002%
2/19/2025	Public Employees Retirement System of Ohio	40,518	$5.53M	0.0%	-5.6%	0.041%
2/18/2025	Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.	53,954	$7.37M	0.9%	-78.2%	0.053%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	1,070,096	$146.07M	0.0%	+19.7%	1.057%
2/17/2025	Worldquant Millennium Advisors LLC	154,852	$21.14M	0.1%	+44.1%	0.153%
2/17/2025	Triglav Skladi D.O.O.	11,000	$1.50M	0.1%	N/A	0.011%
2/17/2025	Two Sigma Investments LP	26,771	$3.65M	0.0%	-70.3%	0.026%
2/17/2025	Tidal Investments LLC	9,425	$1.29M	0.0%	-37.3%	0.009%
2/17/2025	Teza Capital Management LLC	17,864	$2.44M	0.4%	+4.5%	0.018%
2/17/2025	True Wealth Design LLC	444	$61K	0.0%	-25.0%	0.000%
2/17/2025	Strategic Global Advisors LLC	20,521	$2.80M	0.5%	+4.2%	0.020%
2/17/2025	Tema Etfs LLC	3,846	$0.53M	0.2%	N/A	0.004%
2/17/2025	Toronto Dominion Bank	13,183	$1.80M	0.0%	+3.9%	0.013%
2/17/2025	Sarissa Capital Management LP	309,116	$42.19M	13.1%	-24.7%	0.305%
2/17/2025	Siemens Fonds Invest GmbH	6,225	$0.85M	0.0%	N/A	0.006%
2/17/2025	Sherbrooke Park Advisers LLC	2,921	$0.40M	0.1%	-45.0%	0.003%
2/17/2025	Rafferty Asset Management LLC	107,011	$14.61M	0.1%	-24.0%	0.106%
2/17/2025	Raiffeisen Bank International AG	11,400	$1.56M	0.0%	N/A	0.011%
2/17/2025	ProShare Advisors LLC	9,532	$1.30M	0.0%	-54.0%	0.009%
2/17/2025	Quantinno Capital Management LP	3,963	$0.54M	0.0%	+77.0%	0.004%
2/17/2025	Parkman Healthcare Partners LLC	115,727	$15.80M	2.1%	-10.9%	0.114%
2/17/2025	Man Group plc	145,164	$19.82M	0.1%	-51.0%	0.143%
2/17/2025	Nissay Asset Management Corp Japan ADV	12,186	$1.70M	0.0%	+1.2%	0.012%
2/17/2025	Nomura Holdings Inc.	13,434	$1.83M	0.0%	+16.8%	0.013%
2/17/2025	Nuveen Asset Management LLC	267,980	$36.58M	0.0%	-22.5%	0.265%
2/17/2025	OMERS ADMINISTRATION Corp	4,134	$0.56M	0.0%	+20.9%	0.004%
2/17/2025	Orbimed Advisors LLC	938,120	$128.05M	2.8%	+210.4%	0.927%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	9,206	$1.26M	0.0%	-22.8%	0.009%
2/17/2025	Lazard Asset Management LLC	59,279	$8.09M	0.0%	-20.9%	0.059%
2/17/2025	Lighthouse Investment Partners LLC	15,000	$2.05M	0.1%	N/A	0.015%
2/17/2025	Integral Health Asset Management LLC	160,000	$21.84M	1.9%	N/A	0.158%
2/17/2025	Investment Management Corp of Ontario	4,590	$0.63M	0.0%	-3.9%	0.005%
2/17/2025	Iron Triangle Partners LP	318,195	$43.43M	4.8%	N/A	0.314%
2/17/2025	Jacobs Levy Equity Management Inc.	67,189	$9.17M	0.0%	-87.2%	0.066%
2/17/2025	Janus Henderson Group PLC	794,118	$108.40M	0.1%	+0.2%	0.784%
2/17/2025	Hudson Bay Capital Management LP	30,342	$4.14M	0.0%	-24.1%	0.030%
2/17/2025	Gotham Asset Management LLC	5,714	$0.78M	0.0%	-62.7%	0.006%
2/17/2025	Focus Partners Wealth	51,078	$6.97M	0.0%	+9.5%	0.050%
2/17/2025	Ethic Inc.	4,192	$0.57M	0.0%	+34.4%	0.004%
2/17/2025	Ensign Peak Advisors Inc	173,694	$23.71M	0.0%	-0.7%	0.172%
2/17/2025	D. E. Shaw & Co. Inc.	28,710	$3.92M	0.0%	-83.1%	0.028%
2/17/2025	Deutsche Bank AG	461,782	$63.03M	0.0%	+5.5%	0.456%
2/17/2025	DAFNA Capital Management LLC	71,615	$9.78M	2.5%	+2.9%	0.071%
2/17/2025	Deerfield Management Company L.P. Series C	862,000	$117.66M	2.2%	-34.5%	0.851%
2/17/2025	Driehaus Capital Management LLC	102,921	$14.05M	0.1%	+45.4%	0.102%
2/17/2025	EP Wealth Advisors LLC	3,811	$0.52M	0.0%	-9.1%	0.004%
2/17/2025	Cetera Investment Advisers	8,169	$1.12M	0.0%	+46.5%	0.008%
2/17/2025	Cercano Management LLC	24,000	$3.28M	0.1%	N/A	0.024%
2/17/2025	Braidwell LP	901,790	$123.09M	3.7%	-1.7%	0.891%
2/17/2025	Brevan Howard Capital Management LP	6,600	$0.90M	0.0%	+8.3%	0.007%
2/17/2025	Captrust Financial Advisors	11,644	$1.59M	0.0%	+18.7%	0.012%
2/17/2025	Avidity Partners Management LP	220,400	$30.09M	3.0%	-52.1%	0.218%
2/17/2025	Brown Advisory Inc.	898,293	$122.62M	0.2%	-4.7%	0.887%
2/17/2025	Baird Financial Group Inc.	54,717	$7.47M	0.0%	+82.0%	0.054%
2/17/2025	Balyasny Asset Management L.P.	194,728	$26.58M	0.0%	N/A	0.192%
2/17/2025	Bellevue Group AG	1,820,000	$248.43M	4.8%	-2.4%	1.798%
2/17/2025	Bank of America Corp DE	484,034	$66.07M	0.0%	-22.4%	0.478%
2/17/2025	BNP Paribas Financial Markets	289,840	$39.56M	0.0%	-45.7%	0.286%
2/17/2025	Ameriprise Financial Inc.	413,479	$56.44M	0.0%	-16.7%	0.408%
2/17/2025	Algert Global LLC	34,166	$4.66M	0.1%	+86.0%	0.034%
2/17/2025	Alyeska Investment Group L.P.	248,928	$33.98M	0.1%	N/A	0.246%
2/17/2025	AXA S.A.	297,704	$40.64M	0.1%	+10.6%	0.294%
2/17/2025	AlTi Global Inc.	5,086	$0.73M	0.0%	N/A	0.005%
2/14/2025	Mercer Global Advisors Inc. ADV	12,112	$1.65M	0.0%	+52.0%	0.012%
2/14/2025	Keel Point LLC	1,732	$0.24M	0.0%	N/A	0.002%
2/14/2025	Caisse DE Depot ET Placement DU Quebec	748,359	$102.15M	0.2%	+1.6%	0.739%
2/14/2025	Comerica Bank	33,446	$4.57M	0.0%	-4.0%	0.033%
2/14/2025	Utah Retirement Systems	16,583	$2.26M	0.0%	+0.6%	0.016%
2/14/2025	Soros Fund Management LLC	200,000	$27.30M	0.4%	+33.3%	0.198%
2/14/2025	PDT Partners LLC	34,748	$4.74M	0.4%	+133.2%	0.034%
2/14/2025	Schonfeld Strategic Advisors LLC	7,200	$0.98M	0.0%	-70.3%	0.007%
2/14/2025	AQR Capital Management LLC	1,896,891	$258.93M	0.3%	+2.9%	1.873%
2/14/2025	AdvisorShares Investments LLC	2,030	$0.28M	0.1%	N/A	0.002%
2/14/2025	Northern Trust Corp	981,939	$134.04M	0.0%	+27.3%	0.970%
2/14/2025	The Manufacturers Life Insurance Company	110,309	$15.06M	0.0%	-5.9%	0.109%
2/14/2025	Public Employees Retirement Association of Colorado	10,989	$1.50M	0.0%	-1.1%	0.011%
2/14/2025	Quarry LP	1,700	$0.23M	0.0%	-32.0%	0.002%
2/14/2025	Susquehanna Fundamental Investments LLC	114,661	$15.65M	0.2%	N/A	0.113%
2/14/2025	DE Burlo Group Inc.	4,617	$0.63M	0.1%	-9.8%	0.005%
2/14/2025	Virtus ETF Advisers LLC	2,758	$0.38M	0.2%	+14.1%	0.003%
2/14/2025	Coldstream Capital Management Inc.	4,079	$0.56M	0.0%	+4.1%	0.004%
2/14/2025	Nebula Research & Development LLC	14,886	$2.03M	0.2%	-2.2%	0.015%
2/14/2025	Kovitz Investment Group Partners LLC	1,907	$0.26M	0.0%	N/A	0.002%
2/14/2025	Voya Investment Management LLC	139,441	$19.03M	0.0%	+13.3%	0.138%
2/14/2025	Integrated Wealth Concepts LLC	2,707	$0.37M	0.0%	+38.8%	0.003%
2/14/2025	Banco Bilbao Vizcaya Argentaria S.A.	139,670	$19.07M	0.2%	+0.7%	0.138%
2/14/2025	Syon Capital LLC	4,666	$0.64M	0.1%	N/A	0.005%
2/14/2025	Coppell Advisory Solutions LLC	190	$26K	0.0%	-56.5%	0.000%
2/14/2025	Hood River Capital Management LLC	355,058	$48.47M	0.7%	+34.9%	0.351%
2/14/2025	Pinebridge Investments L.P.	30,115	$4.11M	0.0%	-0.7%	0.030%
2/14/2025	Price T Rowe Associates Inc. MD	1,490,513	$203.46M	0.0%	-11.0%	1.472%
2/14/2025	Dark Forest Capital Management LP	1,625	$0.22M	0.0%	N/A	0.002%
2/14/2025	Hsbc Holdings PLC	212,354	$29M	0.0%	-4.9%	0.210%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $110.75

$108.03

$111.27

50 Day Range

MA: $129.69

$107.22

$153.29

52 Week Range

Now: $110.75

$105.18

$157.98

Volume

1,070,142 shs

Average Volume

1,343,585 shs

Market Capitalization

$11.04 billion

P/E Ratio

33.66

Dividend Yield

N/A

Beta

0.35

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Kevin Charles Gorman (Director)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (CEO)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
Shalini Sharp (Director)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Vanguard Group Inc. — 9.99%
Dodge & Cox — 2.98%
Renaissance Technologies LLC — 2.46%
AQR Capital Management LLC — 1.87%
Geode Capital Management LLC — 1.85%
Bellevue Group AG — 1.80%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Jacobs Levy Equity Management Inc.
Deerfield Management Company L.P. Series C
Amundi
Robeco Institutional Asset Management B.V.
BNP Paribas Financial Markets
Avidity Partners Management LP
Pictet Asset Management Holding SA
Rock Springs Capital Management LP
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Kevin Charles Gorman (Director)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (CEO)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
Dodge & Cox
Raymond James Financial Inc.
Wellington Management Group LLP
Thrivent Financial for Lutherans
Orbimed Advisors LLC
Jennison Associates LLC
Norges Bank
Iron Triangle Partners LP